Lupin has signed a $700-million licensing agreement with Germany's Boehringer Ingelheim to develop a drug for patients suffering from difficult-to-treat cancers. Lupin will receive an upfront payment of $20 million, while additional payments will be based on successful achievement of clinical, regulatory and commercial milestones. It's also entitled to receive royalties on sales of the product.